Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Lettis

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
The Lancet. Respiratory Medicine|July 9, 2019
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trialSteven Pascoe, Neil Barnes, Guy Brusselle, et al.
American Journal of Respiratory and Critical Care Medicine|March 13, 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Courtney Crim, Gerard J Criner, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|November 6, 2020
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America RegionsArnaud Bourdin, Gerard Criner, Gilles Devouassoux, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
The Lancet. Respiratory Medicine|July 9, 2019
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trialSteven Pascoe, Neil Barnes, Guy Brusselle, et al.
American Journal of Respiratory and Critical Care Medicine|March 13, 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Courtney Crim, Gerard J Criner, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|November 6, 2020
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America RegionsArnaud Bourdin, Gerard Criner, Gilles Devouassoux, et al.
Pageof 3